Nanotechnology based therapeutic application in cancer diagnosis and therapy

Singh, Ragini

doi:10.1007/s13205-019-1940-0

Cited by 45 publications

(21 citation statements)

References 165 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Theranostics, the trend of biomedicine, which implies the creation of supramolecular complexes with diagnostic and therapeutic properties, fully meets its requirements [ 1 , 2 ]. The study of the molecular peculiarities of tumors and the development of nanotechnology have made it possible to create a number of promising agents based on nanomaterials and intended for diagnostics and targeted therapy [ 3 , 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer

et al. 2020

View full text Add to dashboard Cite

Theranostic approach is currently among the fastest growing trends in cancer treatment. It implies the creation of multifunctional agents for simultaneous precise diagnosis and targeted impact on tumor cells. A new type of theranostic complexes was created based on NaYF4: Yb,Tm upconversion nanoparticles coated with polyethylene glycol and functionalized with the HER2-specific recombinant targeted toxin DARPin-LoPE. The obtained agents bind to HER2-overexpressing human breast adenocarcinoma cells and demonstrate selective cytotoxicity against this type of cancer cells. Using fluorescent human breast adenocarcinoma xenograft models, the possibility of intravital visualization of the UCNP-based complexes biodistribution and accumulation in tumor was demonstrated.

show abstract

Section: Introductionmentioning

confidence: 99%

UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In principle AMPs could be combined with (i) conventional tuberculosis drugs in accordance with drug susceptibility testing, (ii) adjuvants which promote effector mechanisms of macrophages, or (iii) molecules that optimize the targeting of AMPs to the site of infection. One approach to achieve this goal is the design of multipurpose nanoparticles, which serve as a delivery vehicle for multiple bioactive molecules ( Singh, 2019 ). Toward this goal, we initially generated liposomes containing a DDB backbone, the adjuvant trehalose dibehenat (TDB), and Angie1.…”

Section: Discussionmentioning

confidence: 99%

“…Another promising delivery platform are mesoporous nanoparticles, which have been used to deliver antimicrobial peptides, such as NZX and LL-37 ( Braun et al, 2016 ; Tenland et al, 2019 ) to enhance protection against tuberculosis in mice ( Tenland et al, 2019 ). Nanoparticles also promote stability, bioavailability, and efficacy of conventional antituberculotic drugs ( Clemens et al, 2012 ; Singh, 2019 ). These studies will guide the development of multipurpose nanoparticles combining Angie1, antibiotics, and adjuvants to achieve optimized antimicrobial activity at the site of infection.…”

Section: Discussionmentioning

confidence: 99%

Unbiased Identification of Angiogenin as an Endogenous Antimicrobial Protein With Activity Against Virulent Mycobacterium tuberculosis

et al. 2021

View full text Add to dashboard Cite

Tuberculosis is a highly prevalent infectious disease with more than 1.5 million fatalities each year. Antibiotic treatment is available, but intolerable side effects and an increasing rate of drug-resistant strains of Mycobacterium tuberculosis (Mtb) may hamper successful outcomes. Antimicrobial peptides (AMPs) offer an alternative strategy for treatment of infectious diseases in which conventional antibiotic treatment fails. Human serum is a rich resource for endogenous AMPs. Therefore, we screened a library generated from hemofiltrate for activity against Mtb. Taking this unbiased approach, we identified Angiogenin as the single compound in an active fraction. The antimicrobial activity of endogenous Angiogenin against extracellular Mtb could be reproduced by synthetic Angiogenin. Using computational analysis, we identified the hypothetical active site and optimized the lytic activity by amino acid exchanges. The resulting peptide-Angie1-limited the growth of extra‐ and intracellular Mtb and the fast-growing pathogens Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Toward our long-term goal of evaluating Angie1 for therapeutic efficacy in vivo, we demonstrate that the peptide can be efficiently delivered into human macrophages via liposomes and is not toxic for zebrafish embryos. Taken together, we define Angiogenin as a novel endogenous AMP and derive the small, bioactive fragment Angie1, which is ready to be tested for therapeutic activity in animal models of tuberculosis and infections with fast-growing bacterial pathogens.

show abstract

“…GNPs, for example, would be used in cancer screening in vitro studies, in vivo imaging improvement, and as potential drug loading strategies. Aside from that, different preparation methods alter particle sizes, shapes, and structures, reducing their clinical utility [ 76 , 77 , 78 , 79 ].…”

Section: Diagnosis Of Bladder Cancermentioning

confidence: 99%

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Barani

Hosseinikhah

Rahdar

et al. 2021

Cancers

View full text Add to dashboard Cite

Bladder cancer (BC) is the second most common cancer of the urinary tract in men and the fourth most common cancer in women, and its incidence rises with age. There are many conventional methods for diagnosis and treatment of BC. There are some current biomarkers and clinical tests for the diagnosis and treatment of BC. For example, radiotherapy combined with chemotherapy and surgical, but residual tumor cells mostly cause tumor recurrence. In addition, chemotherapy after transurethral resection causes high side effects, and lack of selectivity, and low sensitivity in sensing. Therefore, it is essential to improve new procedures for the diagnosis and treatment of BC. Nanotechnology has recently sparked an interest in a variety of areas, including medicine, chemistry, physics, and biology. Nanoparticles (NP) have been used in tumor therapies as appropriate tools for enhancing drug delivery efficacy and enabling therapeutic performance. It is noteworthy, nanomaterial could be reduced the limitation of conventional cancer diagnosis and treatments. Since, the major disadvantages of therapeutic drugs are their insolubility in an aqueous solvent, for instance, paclitaxel (PTX) is one of the important therapeutic agents utilized to treating BC, due to its ability to prevent cancer cell growth. However, its major problem is the poor solubility, which has confirmed to be a challenge when improving stable formulations for BC treatment. In order to reduce this challenge, anti-cancer drugs can be loaded into NPs that can improve water solubility. In our review, we state several nanosystem, which can effective and useful for the diagnosis, treatment of BC. We investigate the function of metal NPs, polymeric NPs, liposomes, and exosomes accompanied therapeutic agents for BC Therapy, and then focused on the potential of nanotechnology to improve conventional approaches in sensing.

show abstract

Nanotechnology based therapeutic application in cancer diagnosis and therapy

Cited by 45 publications

References 165 publications

UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer

UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer

Unbiased Identification of Angiogenin as an Endogenous Antimicrobial Protein With Activity Against Virulent Mycobacterium tuberculosis

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Contact Info

Product

Resources

About